Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 54Squamous Cell Carcinoma of Head and Neck 4Sarcoma 4Neoplasm Metastasis 4Sarcoma, Ewing 3Neoplasms 3Medulloblastoma 3Lymphoma, Non-Hodgkin 3Glioma 3Carcinoma, Non-Small-Cell Lung 3Astrocytoma 3Wilms Tumor 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Recurrence 2Osteosarcoma 2Oligodendroglioma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Lymphoma 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioblastoma 2Ependymoma 2Colonic Neoplasms 2Xanthogranuloma, Juvenile 1Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Teratoma 1Recurrent Squamous Cell Lung Carcinoma 1

Interventions

Fulvestrant 4Letrozole 2Goserelin 2Docetaxel 2Dasatinib 2vandetanib 1sonidegib 1pembrolizumab 1palbociclib 1olaparib 1exemestane 1cediranib 1Lead 1Gemcitabine 1Everolimus 1Capecitabine 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Breast Cancer × palbociclib × Clear all
NCT02499146 2026-02-11

Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer

Pfizer

Phase 1 Completed
26 enrolled 40 charts
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡